论文部分内容阅读
１９８７年７月至１９９３年５月临床诊断和治疗前列腺癌９２例，平均年龄６９．２岁，就诊时多为晚期。测定４９例血清前列腺酸性磷酸酶（ＰＡＰ）和５１例前列腺特异性抗原（ＰＳＡ），阳性率分别为５７．１％和８２．４％。ＰＡＰ和ＰＳＡ对判断肿瘤分期、监测病情变化和疗效有较大价值。对４０例病人作前列腺癌细针抽吸活检细胞学检查，此法对前列腺癌的诊断，特别是早期前列腺癌以及分级判断预后有较大价值。随访观察５８例内分泌治疗疗效，双侧睾丸切除、雌激素及促黄体激素释放激素（ＬＨＲＨ）类似物三种方法的疗效均在７０％以上，无明显差异。前列腺癌的死因主要是癌肿骨转移、梗阻性肾功能衰竭和严重血尿。
July 1987 to May 1993 clinical diagnosis and treatment of 92 cases of prostate cancer, the average age of 69.2 years, mostly late treatment. 49 cases of serum prostatic acid phosphatase (PAP) and 51 cases of prostate-specific antigen (PSA) were detected, the positive rates were 57.1% and 82.4% respectively. PAP and PSA to determine the stage of the tumor, monitoring the condition changes and the efficacy of great value. In 40 cases of prostate cancer needle aspiration biopsy cytology, this method of prostate cancer diagnosis, especially in early stage of prostate cancer and grading to determine the prognosis of great value. Follow-up observation of 58 cases of endocrine therapy efficacy, bilateral orchiectomy, estrogen and luteinizing hormone releasing hormone (LHRH) analogues of the three methods are more than 70%, no significant difference. The main cause of death of prostate cancer is cancerous bone metastases, obstructive renal failure and severe hematuria.